Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470177) titled 'A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults' on March 10.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Jemincare

Condition: ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Intervention: Drug: JMKX003142 tablets Drug: JMKX003142 tablets

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 27, 2026

Target Sample Size: 24

To know more, visit https://clinicaltrials.gov/study/NCT0747017...